Precision Optics Corporation, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2023, the first quarter of fiscal 2024. The comparative period is the three months ended September 30, 2022. Financial statements are unaudited.
Business context and results
The company develops and manufactures optical instruments, components, assemblies, and medical visualization products. Its business includes medical-device engineering and manufacturing, custom optical components through Ross Optical, and imaging systems through Lighthouse Imaging.
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Revenue | $4.32 million | $5.09 million | Down 15.0% |
| Gross profit | $1.46 million | $1.64 million | Down 10.7% |
| Gross margin | 33.9% | 32.2% | Up 1.7 percentage points |
| Operating loss | $405,293 | $101,802 | Loss increased |
| Net loss | $464,415 | $158,724 | Loss increased |
| Loss per share, basic and diluted | $0.08 | $0.03 | Loss per share increased |
| Operating cash flow | $(1.37) million | $199,734 | Shifted to cash use |
Engineering design services revenue increased to $1.90 million from $1.64 million. Optical components revenue fell to $1.90 million from $2.65 million, and medical device products and assemblies fell to $517,000 from $790,000. Research and development expense declined 13.3% to $213,000; selling, general and administrative expense rose 8.2% to $1.66 million, mainly from marketing, personnel, and public-company costs. Management attributed the higher gross margin partly to improved utilization of engineering resources.
Liquidity, debt, and balance sheet
- Cash and cash equivalents were $1.37 million at September 30, 2023, down from $2.93 million at June 30, 2023. The cash-flow statement reports a quarterly decrease of $1.56 million.
- Current assets were $9.24 million and current liabilities were $5.13 million. Accounts receivable was $4.53 million; inventory was $2.97 million.
- Long-term debt had $2.60 million of principal outstanding before current maturities and debt issuance costs; $513,259 was classified as current. The loans are secured by company assets and carry fixed rates of 7.0% and 8.625%. Capital lease obligations totaled $101,129.
- A $1.25 million revolving credit facility was undrawn at quarter-end and reported as fully available. It is due on demand and subject to a borrowing base.
- Operating cash use reflected, among other items, higher receivables and inventory and lower accounts payable. Investing cash outflow was $43,517; financing cash outflow was $138,876.
- Open purchase orders represented approximately $2.06 million of contractual commitments. The company also reported future lease and debt payments.
Outlook, risks, and other notable items
Management said lower optical-component sales reflected customers reducing inventories after elevated ordering amid supply-chain concerns. Lower assembly revenue reflected timing between mature program exits, reorders, and new program launches. Increased engineering revenue was associated with design work for products expected to move toward commercial production later in the fiscal year. No quantified revenue or earnings guidance was provided.
Management described intense competition, including larger competitors with greater resources, and noted that results depend on sales volume, product mix, utilization, engineering costs, project changes, and delays. The company expects to continue pursuing design and development work and selectively investing in medical optics and endoscopy technologies. Its term loans include an annual minimum EBITDA plus stock-based-compensation-to-debt-service coverage ratio of 1.20:1; the filing does not clearly state covenant compliance for this quarter. Management reported no estimated goodwill or patent impairment, no material off-balance-sheet arrangements, and no known pending or threatened litigation expected to materially affect operations or finances. Disclosure controls and internal control over financial reporting were assessed as effective at September 30, 2023.
Important facts for investors to verify
- The MD&A gives quarter-end cash as $1,370,769, while the balance sheet and cash-flow statement report $1,370,469. Confirm the correct amount.
- The stock-option note reports 1,023,140 options outstanding at September 30, but separately says approximately 1,123,140 options were excluded from diluted-share calculations. Confirm the correct option count.
- Monitor whether the expected transition of engineering projects into production offsets lower component and assembly demand, and whether customer inventory normalization continues.
- Assess cash burn, receivables and inventory conversion, access to the demand line of credit, and compliance with secured-loan covenants.